Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.

Item

http://www.wikidata.org/entity/Q38898477

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.

@en

type

Item

label

Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.

@en

prefLabel

Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.

@en

P1476

Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.

@en

P2093

Kazunari Tanabe

http://www.w3.org/2001/XMLSchema#string

Kazuya Omoto

http://www.w3.org/2001/XMLSchema#string

Kengo Sakaguchi

http://www.w3.org/2001/XMLSchema#string

Masahiko Miura

http://www.w3.org/2001/XMLSchema#string

Naoki Kohei

http://www.w3.org/2001/XMLSchema#string

Yugo Sawada

http://www.w3.org/2001/XMLSchema#string

P2860

Angiogenesis in cancer, vascular, rheumatoid and other disease

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

In vivo anti-tumour effect of 3'-sulphonoquinovosyl 1'-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine

Rising prostate-specific antigen after primary prostate cancer therapy.

Epidemiology of prostate cancer in the Asia-Pacific region.

P304

590-595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJU.12753

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25781902

http://www.w3.org/2001/XMLSchema#string